Webinars: Insights on Duchenne muscular dystrophy (DMD) from leading experts.
Dyne Therapeutics will present initial clinical data, first released on January 3rd, 2024, from the DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
Join PTC Therapeutics and CureDuchenne for this prerecorded webinar to hear important information regarding Emflaza, PTC Cares and the programs that support the Duchenne community. Topics include:Understanding Your PrescriptionHow to Ensure Your Son […]
Join us for this pre-recorded presentation and Q&A discussing to learn about a new FDA-approved treatment for Duchenne muscular dystrophy. During the session, Catalyst Pharmaceuticals will provide an overview of […]
Join us for this pre-recorded presentation and Q&A discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 for the treatment of individuals with Duchenne muscular dystrophy (DMD) who are amenable […]
Join Edgewise’s Chief Scientific Officer and Chief Medical Officer to discuss the clinical development program for EDG-5506, a myosin modulator, that aims to prevent muscle damage in Becker and Duchenne […]
For those with Duchenne, maintaining respiratory strength and health contributes to health-related quality of life and some assessment and treatment is within our scope of practice as therapists. This webinar […]
VILTEPSO: AN FDA-APPROVED TREATMENT FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO EXON 53 SKIPPING This is a pre-recorded webinar with CureDuchenne, NS Pharma and guest speaker Dr. Mathula […]
REGENXBIO’s Senior Director and Clinical Development Lead, Dr. Jahannaz Dastgir and Dr. Veerapandiyan from Arkansas Children’s Hospital share updates about RGX-202, an investigational gene therapy for the treatment of Duchenne […]
A Clinical Trial Investigating the Potential for AOC 1044 to Treat Individuals with DMD Mutations Amenable to Exon 44 Skipping Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and […]
